Oricell Invited to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

Shanghai, China, September 10, 2025 -- Oricell Therapeutics ("Oricell"), a clinical-stage biotech company at the forefront of oncology immunotherapy and advanced cell therapy development, today announced that Dr. Peter He, Oricell's co-founder and chief scientific officer, presented Oricell's proprietary technology platform, pipeline progress, global footprint, and strategic vision at the Morgan Stanley 23rd Annual Global Healthcare Conference taking place on September 8th-10th in New York City.

About Oricell Therapeutics

Oricell is a clinical-stage biotechnology company dedicated to developing innovative cell therapies to address unmet medical needs in oncology and immunology around the world. With Ori®Ab, Ori®CAR technology platforms, and unique CMC know-how, Oricell has developed a broad portfolio of pipeline programs for the treatment of hematologic malignancies and solid tumors. These therapies have demonstrated well-tolerated and substantial efficacy in exploratory clinical studies. The related clinical results were presented at international conferences and published in international academic journals, including the 2021 ASCO, 2022 ASCO, 2022 EHA, 2024 ASCO, 2024 SITC, 2024 ASH and The Lancet Haematology.

Forward-Looking Statements

This press release contains “forward-looking statements” which are not historical facts, but instead are predictions about future events based on the beliefs as well as assumptions made by and information currently available to the management of Oricell Therapeutics Holdings Limited (the “Company” or “Oricell”). The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company, or industry results, to differ materially from any future results, performance or achievement implied by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date of this press release. The Company assumes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.